Alhena Science

Alhena Science is an Italian private biotech company developing cell and gene therapies for liquid tumours. The company focuses on identifying tumour-specific antigens and using them to engineer chimeric antigen receptor T-cell therapies intended to selectively eliminate cancer cells while sparing healthy tissues. Its lead disclosed application is in acute myeloid leukemia, where it has reported preclinical safety and efficacy data. Alhena Science appears to have been founded by Altheia Science through the transfer of oncology projects and related intellectual property. The company is headquartered in Milan and is positioning itself around curative immuno-gene therapy approaches for hematologic malignancies.